Visirna Therapeutics
About:
Visirna Therapeutics to develop and commercialize RNAi therapeutics targeting cardiovascular and metabolic diseases.
Top Investors: Vivo Capital
Description:
Arrowhead and Vivo formed Visirna Therapeutics as a joint venture to bring four of the biotech's RNAi therapies to China. Through a licensing agreement, the company will focus on four of Arrowhead's therapies for cardiometabolic diseases.
Total Funding Amount:
$60M
Headquarters Location:
Shanghai, Shanghai, China
Founded Date:
2022-01-01
Founders:
Number of Employees:
Last Funding Date:
2022-04-25
IPO Status:
Private
Industries:
© 2025 bioDAO.ai